Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Spinal cord dose tolerance to stereotactic body radiotherapy. International journal of radiation oncology, biology, physics Sahgal, A., Chang, J. H., Ma, L., Marks, L. B., Milano, M. T., Medin, P., Niemierko, A., Soltys, S. G., Tome, W. A., Wong, C. S., Yorke, E., Grimm, J., Jackson, A. 2019

Abstract

Spinal cord tolerance data for stereotactic body radiotherapy (SBRT) were extracted from published reports, reviewed and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1 - 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions and 25.3 Gy in 5 fractions. For re-irradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include: cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD22) Dmax = 70 Gy; SBRT thecal sac EQD22 Dmax = 25 Gy, thecal sac SBRT EQD22 Dmax to cumulative EQD22 Dmax ratio = 0.5, and a minimum time interval to re-irradiation of = 5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates.

View details for DOI 10.1016/j.ijrobp.2019.09.038

View details for PubMedID 31606528